[Value of new prostate cancer markers: alpha methylacyl CoA racemase (P504S) and p63].
The diagnosis of prostate cancer is based on histological examination of prostatic biopsies using histological criteria identified on standard stains. In certain lesions mimicking prostate cancer, the pathologist must perform immunohistochemical studies looking for loss of basal cells and antibodies directed against cytokeratin CK 903 (34bE12) or CK5/6, which sometimes give inconclusive results leading to a diagnosis of suspicious site. The discovery of overexpression of alpha-méthylacyl CoA racemase in prostate cancer using a microarray technique has allowed the development and marketing of an antibody (P504S /AMACR) which, in combination with a new basal cell marker (p63), is a very valuable tool for the pathologist in the management of suspicious sites and cancers less than 1 mm in diameter detected on prostatic biopsies.
Molinié
Vincent
V
Service d'Anatomie et Cytologie Pathologiques, Hôpital Saint Joseph, Paris, France. vmolinie@hopital-saint-joseph.org
Hervé
Jean-Marie
JM
Lugagne
Pierre-Marie
PM
Yonneau
Laurent
L
Ellard
Stéphane
S
Lebret
Thierry
T
Botto
Henry
H
D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000473:pathology*; D019998:Racemases and Epimerases / Q000032:analysis*
C081876:CKAP4 protein, human; D008565:Membrane Proteins; D019998:Racemases and Epimerases; C108352:alpha-methylacyl-CoA racemase